We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Read MoreHide Full Article
Key Takeaways
Jazz gains worldwide rights to Saniona's investigational epilepsy drug SAN2355.
The drug targets Kv7.2/Kv7.3 channels to avoid past safety issues seen with Potiga.
Through the deal with Saniona, Jazz expands its neuroscience pipeline, furthering its success with Epidiolex.
JAZZ Pharmaceuticals (JAZZ - Free Report) announced that it has signed an agreement with Denmark-based biopharmaceutical company Saniona to acquire worldwide rights to the latter’s investigational epilepsy drug, SAN2355.
SAN2355 is a selective, small-molecule activator of Kv7.2/Kv7.3 potassium channels — a mechanism both Jazz and Saniona claim is valid for seizure suppression. Unlike earlier therapies, the drug is specifically designed to avoid activating other Kv7 subtypes. This distinction is critical, as seen with GSK’s (GSK - Free Report) Potiga, which once showed clinical benefit in the same pathway but was withdrawn in 2017 due to safety issues linked to off-target Kv7 activation and limited market uptake.
Through SAN2355, Jazz/Saniona aim to avoid the concerns associated with GSK’s Potiga by focusing exclusively on the Kv7 targets directly linked to seizure control.
Per the terms of the deal, Jazz will take charge of SAN2355’s clinical development and commercialization. In exchange, Saniona will receive an upfront cash payment of $42.5 million and remain eligible for milestone payments of up to $192.5 million tied to development and regulatory achievements, along with up to $800 million linked to commercial milestones. Jazz will also pay Saniona royalties on future sales of the drug.
JAZZ Stock’s Performance
Year to date, shares of the company have lost 3% against the industry’s 3% growth.
Image Source: Zacks Investment Research
What is JAZZ’s Intent Behind the Deal?
Through this deal, JAZZ Pharmaceuticals intends to expand its neuroscience pipeline. The company already has a significant exposure in the epilepsy space with its marketed drug, Epidiolex, which is expected to achieve blockbuster status this year. What differentiates Epidiolex from other epilepsy treatments is that it remains the only FDA-approved therapy containing a purified drug substance derived from marijuana.
The addition of SAN2355 indicates that Jazz is preparing for the next wave of innovation in epilepsy, potentially positioning the drug as a successor to Epidiolex once it loses exclusivity, while reinforcing the company’s long-term strength in the neuroscience market.
Notably, Saniona initiated manufacturing and toxicology studies on SAN2355 with funds secured from its deal with Acadia Pharmaceuticals (ACAD - Free Report) last year. Under the terms of that agreement, Acadia acquired exclusive rights to the essential tremor candidate SAN711 for $28 million upfront, with the potential value of the transaction reaching up to $600 million through development, regulatory and commercial milestone payments.
Image: Bigstock
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Key Takeaways
JAZZ Pharmaceuticals (JAZZ - Free Report) announced that it has signed an agreement with Denmark-based biopharmaceutical company Saniona to acquire worldwide rights to the latter’s investigational epilepsy drug, SAN2355.
SAN2355 is a selective, small-molecule activator of Kv7.2/Kv7.3 potassium channels — a mechanism both Jazz and Saniona claim is valid for seizure suppression. Unlike earlier therapies, the drug is specifically designed to avoid activating other Kv7 subtypes. This distinction is critical, as seen with GSK’s (GSK - Free Report) Potiga, which once showed clinical benefit in the same pathway but was withdrawn in 2017 due to safety issues linked to off-target Kv7 activation and limited market uptake.
Through SAN2355, Jazz/Saniona aim to avoid the concerns associated with GSK’s Potiga by focusing exclusively on the Kv7 targets directly linked to seizure control.
Per the terms of the deal, Jazz will take charge of SAN2355’s clinical development and commercialization. In exchange, Saniona will receive an upfront cash payment of $42.5 million and remain eligible for milestone payments of up to $192.5 million tied to development and regulatory achievements, along with up to $800 million linked to commercial milestones. Jazz will also pay Saniona royalties on future sales of the drug.
JAZZ Stock’s Performance
Year to date, shares of the company have lost 3% against the industry’s 3% growth.
Image Source: Zacks Investment Research
What is JAZZ’s Intent Behind the Deal?
Through this deal, JAZZ Pharmaceuticals intends to expand its neuroscience pipeline. The company already has a significant exposure in the epilepsy space with its marketed drug, Epidiolex, which is expected to achieve blockbuster status this year. What differentiates Epidiolex from other epilepsy treatments is that it remains the only FDA-approved therapy containing a purified drug substance derived from marijuana.
The addition of SAN2355 indicates that Jazz is preparing for the next wave of innovation in epilepsy, potentially positioning the drug as a successor to Epidiolex once it loses exclusivity, while reinforcing the company’s long-term strength in the neuroscience market.
Notably, Saniona initiated manufacturing and toxicology studies on SAN2355 with funds secured from its deal with Acadia Pharmaceuticals (ACAD - Free Report) last year. Under the terms of that agreement, Acadia acquired exclusive rights to the essential tremor candidate SAN711 for $28 million upfront, with the potential value of the transaction reaching up to $600 million through development, regulatory and commercial milestone payments.
Jazz Pharmaceuticals PLC Price
Jazz Pharmaceuticals PLC price | Jazz Pharmaceuticals PLC Quote
JAZZ’s Zacks Rank
JAZZ currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.